Graybill Bartz Assoc Ltd Lowers stake in Hologic (HOLX)

Hologic (HOLX) : Graybill Bartz Assoc Ltd reduced its stake in Hologic by 2.76% during the most recent quarter end. The investment management company now holds a total of 57,000 shares of Hologic which is valued at $2,098,740 after selling 1,615 shares in Hologic , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.Hologic makes up approximately 1.86% of Graybill Bartz Assoc Ltd’s portfolio.

Other Hedge Funds, Including , Acadian Asset Management reduced its stake in HOLX by selling 98 shares or 62.03% in the most recent quarter. The Hedge Fund company now holds 60 shares of HOLX which is valued at $2,209. Cribstone Capital Management added HOLX to its portfolio by purchasing 1,000 company shares during the most recent quarter which is valued at $36,820. Hologic makes up approx 0.02% of Cribstone Capital Management’s portfolio. Partnerre Asset Management Corp added HOLX to its portfolio by purchasing 1,631 company shares during the most recent quarter which is valued at $59,434. Hologic makes up approx 0.03% of Partnerre Asset Management Corp’s portfolio.Webster Bank N. A. boosted its stake in HOLX in the latest quarter, The investment management firm added 1,216 additional shares and now holds a total of 39,415 shares of Hologic which is valued at $1,411,057. Hologic makes up approx 0.20% of Webster Bank N. A.’s portfolio.Raymond James Trust N.a. boosted its stake in HOLX in the latest quarter, The investment management firm added 231 additional shares and now holds a total of 21,989 shares of Hologic which is valued at $790,065. Hologic makes up approx 0.07% of Raymond James Trust N.a.’s portfolio.

Hologic opened for trading at $36.57 and hit $36.91 on the upside on Wednesday, eventually ending the session at $36.82, with a gain of 0.88% or 0.32 points. The heightened volatility saw the trading volume jump to 20,31,397 shares. Company has a market cap of $10,267 M.

On the company’s financial health, Hologic reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.46. The company had revenue of $693.30 million for the quarter, compared to analysts expectations of $687.43 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.

Many Wall Street Analysts have commented on Hologic. Hologic was Downgraded by Needham to ” Hold” on Apr 28, 2016.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.